TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38353107

Group type: EXPERIMENTAL
Intervention: Three cycles of neoadjuvant sintilimab + platinum-based chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four cycles of neoadjuvant sintilimab + platinum-based chemotherapy
Number of subjects: 0
Study: 38353215

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 36
Study: 38353219

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Number of subjects: 89

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 89
Study: 38353245

Group type: EXPERIMENTAL
Intervention: Integrative medicine program (9-week duration) with recommendations for an anti-inflammatory Mediterranean diet and self-management support
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Integrative medicine program
Number of subjects: 13
Study: 38353242

Group type: EXPERIMENTAL
Intervention: Distal transradial access (dTRA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Forearm transradial access (fTRA)
Number of subjects: 64
Study: 38353260

Group type: EXPERIMENTAL
Intervention: Screening with an implantable loop recorder and anticoagulation upon detection of new-onset AF episodes ≥6 minutes
Number of subjects: 6004

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6004
Study: 38353265

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) imaging approach using fluorine-18-sodium fluoride
Number of subjects: 8
Study: 38353301

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 372
Study: 38353689

Group type: COMPARATOR
Intervention: ACD856 (1 - 150 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ACD856 (0.100 mg microdose)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ACD856 (oral administration)
Number of subjects: 56
Study: 38353714

Group type: COMPARATOR
Intervention: Conservative screening
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Conservative-aggressive screening
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Aggressive-conservative screening
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Aggressive-aggressive screening
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: All aggressive screening groups combined
Number of subjects: 884
Study: 38353936

Group type: EXPERIMENTAL
Intervention: Surgical procedures
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Mechanical thrombectomy
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Types of thrombectomy
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Types of thrombolysis
Number of subjects: 1176
Study: 38353966

Group type: EXPERIMENTAL
Intervention: Enhanced implementation of best practices
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5887
Study: 38354042

Group type: EXPERIMENTAL
Intervention: Safe City mobile game for 4 weeks
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Safe City mobile game
Number of subjects: 340

Group type: COMPARATOR
Intervention: Safety booklet
Number of subjects: 340
Study: 38354066

Group type: EXPERIMENTAL
Intervention: Zinpentraxin Alfa
Number of subjects: 0
Study: 38354138

Group type: EXPERIMENTAL
Intervention: 1200 mg of frexalimab intravenously every 4 weeks (with an 1800-mg loading dose)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 300 mg of frexalimab subcutaneously every 2 weeks (with a 600-mg loading dose)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 38354139

Group type: EXPERIMENTAL
Intervention: E-cigarettes and e-liquids, standard-of-care smoking-cessation counseling, optional nicotine-replacement therapy
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Standard counseling and a voucher for any purpose (including nicotine-replacement therapy)
Number of subjects: 1246
Study: 38354140

Group type: EXPERIMENTAL
Intervention: Cefepime-taniborbactam (2.5 g) every 8 hours for 7 days (up to 14 days if bacteremia)
Number of subjects: 661

Group type: COMPARATOR
Intervention: Meropenem (1 g) every 8 hours for 7 days (up to 14 days if bacteremia)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Cefepime-taniborbactam
Number of subjects: 661
Study: 38354330

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 40
Study: 38354481

Group type: EXPERIMENTAL
Intervention: glargine
Number of subjects: 4098

Group type: EXPERIMENTAL
Intervention: glimepiride
Number of subjects: 4098

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 4098

Group type: EXPERIMENTAL
Intervention: sitagliptin
Number of subjects: 4098

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4098
Study: 38354535

Group type: EXPERIMENTAL
Intervention: Canakinumab plus docetaxel
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 237
Study: 38354688

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy (PD1/PD-L1 antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-source dual-energy computed tomography (ssDECT)
Number of subjects: 0
Study: 38354904

Group type: EXPERIMENTAL
Intervention: High protein treatment (1.6 g/kg per day)
Number of subjects: 1301

Group type: COMPARATOR
Intervention: Usual protein treatment (0.9 g/kg per day)
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Preexisting malnutrition
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: High protein treatment in patients with preexisting malnutrition
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: High protein treatment in patients without preexisting malnutrition
Number of subjects: 1301
Study: 38354997

Group type: EXPERIMENTAL
Intervention: Gamification strategy to increase daily physical activity, including a wearable fitness tracker and a goal to increase daily step count by 33%-50% over 16 weeks.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gamification strategy to increase daily physical activity.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control arm (no gamification strategy).
Number of subjects: 102
Study: 38355174

Group type: EXPERIMENTAL
Intervention: 3D convolutional network-based analysis of screening chest CT scans
Number of subjects: 2722

Group type: COMPARATOR
Intervention: Standard lung cancer screening (LCS) without AI assistance
Number of subjects: 2722
Study: 38355178

Group type: EXPERIMENTAL
Intervention: Sleep in the subacute phase of recovery
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Motor consolidation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Electrophysiological sleep signals and sleep alterations during subacute recovery
Number of subjects: 150
Study: 38355180

Group type: EXPERIMENTAL
Intervention: WiserAD approach to antidepressant deprescribing
Number of subjects: 13
Study: 38355187

Group type: EXPERIMENTAL
Intervention: FIT Families (FIT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Home-Based Family Support (HBFS)
Number of subjects: 180
Study: 38355190

Group type: EXPERIMENTAL
Intervention: AI as a complementary tool in mammography
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AI implementation in mammography
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AI in decision-making for mammograms
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Expectations from AI compared to radiologists
Number of subjects: 16
Study: 38355195

Group type: EXPERIMENTAL
Intervention: 20% human albumin every 10th day for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo) every 10th day for 6 months
Number of subjects: 0
Study: 38355240

Group type: EXPERIMENTAL
Intervention: Salt substitute (62.5% NaCl, 25% KCl, and 12.5% flavorings)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Usual salt
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Salt substitute
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Salt substitute vs Usual salt
Number of subjects: 611
Study: 38355246

Group type: EXPERIMENTAL
Intervention: Vascular regenerative cell content in South Asian adults
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vascular regenerative cell content in White European adults
Number of subjects: 60
Study: 38355261

Group type: EXPERIMENTAL
Intervention: Distal Radial Access (DRA)
Number of subjects: 4977
Study: 38355269

Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 1454

Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 1454
Study: 38355278

Group type: EXPERIMENTAL
Intervention: High levels of oxidative phosphorylation (OXPHOS) in patients with RCC.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Knockdown of mitochondrial complex I subunit.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 25
Study: 38355289

Group type: EXPERIMENTAL
Intervention: VExUS score for cardiorenal AKI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: IVC maximum diameter >20.4 mm for cardiorenal AKI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: VExUS score for hypovolaemic AKI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: IVC maximum diameter ≤16.8 mm for hypovolaemic AKI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Parameters for renal and systemic vasodilatation subtypes
Number of subjects: 150
Study: 38355397

Group type: EXPERIMENTAL
Intervention: 5-mg midodrine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (metoclopramide)
Number of subjects: 56
Study: 38355421

Group type: EXPERIMENTAL
Intervention: Prediction model based on demographic characteristics, work situation, daily lifestyle, and laboratory tests.
Number of subjects: 824
Study: 38355459

Group type: EXPERIMENTAL
Intervention: MS-TRAM/DIEP breast reconstruction by dual-trained breast surgeons
Number of subjects: 147
Study: 38355528

Group type: EXPERIMENTAL
Intervention: Wiltse TLIF
Number of subjects: 56

Group type: COMPARATOR
Intervention: P-TLIF
Number of subjects: 56
Study: 38355674

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum 1714
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 38355715

Group type: EXPERIMENTAL
Intervention: Kundalini yoga training (KY) - 60-min weekly classes for 12 weeks with daily 12-min homework practice.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Memory enhancement training (MET) - 12 weekly in-person group classes with 12-min daily homework exercises.
Number of subjects: 79
Study: 38355777

Group type: EXPERIMENTAL
Intervention: entinostat + nivolumab + ipilimumab
Number of subjects: 24
Study: 38355814

Group type: EXPERIMENTAL
Intervention: Insulin glargine U300 (Gla-300)
Number of subjects: 412
Study: 38355837

Group type: EXPERIMENTAL
Intervention: Care as Usual plus Youth-Initiated Mentoring (CAU + YIM)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 300
Study: 38355868

Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds (CMBs) presence
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: ASPECTs score
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Collaterals status (adequate vs poor)
Number of subjects: 445
Study: 38355918

Group type: EXPERIMENTAL
Intervention: Noninvasive ICP wave morphology (nICPW) using B4C sensor
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cut-off value of P2/P1 ratio at 1.13
Number of subjects: 69
Study: 38355932

Group type: EXPERIMENTAL
Intervention: Salivary iodine concentration (SIC) < 176 μg/L
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Salivary iodine concentration (SIC) > 529 μg/L
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Salivary iodine concentration (SIC)
Number of subjects: 609
Study: 38355973

Group type: EXPERIMENTAL
Intervention: Retroviral gene therapy for ADA deficiency
Number of subjects: 0
Study: 38356027

Group type: EXPERIMENTAL
Intervention: Bilateral AT LARA
Number of subjects: 71

Group type: COMPARATOR
Intervention: Combined implantation AT LARA/AT LISA tri
Number of subjects: 71
Study: 38356105

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50-200 mg/day
Number of subjects: 0
Study: 38356163

Group type: EXPERIMENTAL
Intervention: Constant Work Rate (CWR) testing at 70% of maximal exercise capacity
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Constant Work Rate (CWR) testing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CWR testing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Incremental testing
Number of subjects: 10
Study: 38356344

Group type: EXPERIMENTAL
Intervention: Tα1 treatment
Number of subjects: 502
Study: 38356447

Group type: EXPERIMENTAL
Intervention: Lenalidomide, rituximab, and methotrexate
Number of subjects: 0
Study: 38356729

Group type: EXPERIMENTAL
Intervention: Induction treatment with sintilimab, paclitaxel, and carboplatin (2 cycles, once every 21 days) followed by concurrent treatment with carboplatin and paclitaxel (5 cycles, once per week) concurrent with radiotherapy (50.4Gy in 28 fractions)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy only (from previous studies)
Number of subjects: 75
Study: 38356731

Group type: EXPERIMENTAL
Intervention: stapokibart 600-300 mg Q2W
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: stapokibart 600-300 mg QW
Number of subjects: 92

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92
Study: 38356837

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care and SMS reminder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 38356864

Group type: EXPERIMENTAL
Intervention: High-dependency units (HDU)
Number of subjects: 4546

Group type: COMPARATOR
Intervention: Intensive care units (ICU)
Number of subjects: 4546

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (IMV) in HDUs
Number of subjects: 4546

Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (IMV) in ICUs
Number of subjects: 4546

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy in HDUs
Number of subjects: 4546

Group type: COMPARATOR
Intervention: Renal replacement therapy in ICUs
Number of subjects: 4546

Group type: EXPERIMENTAL
Intervention: Antibiotic use
Number of subjects: 4546

Group type: EXPERIMENTAL
Intervention: Average length of stay
Number of subjects: 4546

Group type: EXPERIMENTAL
Intervention: Readmission rate
Number of subjects: 4546

Group type: EXPERIMENTAL
Intervention: COVID-19 admissions in ICUs
Number of subjects: 4546
Study: 38356882

Group type: EXPERIMENTAL
Intervention: Personalized digital speech therapy application
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional therapy with a workbook
Number of subjects: 76
Study: 38356884

Group type: EXPERIMENTAL
Intervention: Ravulizumab (2,400-3,000 mg loading dose on day 1, followed by 3,000-3,600 mg maintenance doses on day 15 and once every 8 weeks thereafter)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 58
Study: 38356931

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 31

Group type: COMPARATOR
Intervention: Women
Number of subjects: 31
Study: 38356965

Group type: EXPERIMENTAL
Intervention: Entinostat 3-5 mg and Capecitabine 800 mg
Number of subjects: 13
Study: 38357205

Group type: EXPERIMENTAL
Intervention: BCT-100 (1600U/kg iv weekly)
Number of subjects: 49
Study: 38357391

Group type: EXPERIMENTAL
Intervention: peficitinib 100 mg
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: peficitinib 150 mg
Number of subjects: 385

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: peficitinib
Number of subjects: 385
Study: 38357398

Group type: EXPERIMENTAL
Intervention: Half-dose BNT162b2 (15 μg)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Full-dose BNT162b2 (30 μg)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Half-dose BNT162b2 (15 μg) in Gam-COVID-Vac-primed participants
Number of subjects: 601

Group type: COMPARATOR
Intervention: Full-dose BNT162b2 (30 μg) in Gam-COVID-Vac-primed participants
Number of subjects: 601
Study: 38357416

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (USG)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Sham US
Number of subjects: 290
Study: 38357797

Group type: EXPERIMENTAL
Intervention: SAGE-324/BIIB124 (60 mg once daily for 28 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (once daily for 28 days)
Number of subjects: 69
Study: 38357820

Group type: EXPERIMENTAL
Intervention: BMS-986141 (4 mg single oral dose)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of ticagrelor (90 mg BID) and aspirin (75 mg QD)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg BID)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg QD)
Number of subjects: 45
Study: 38358253

Group type: EXPERIMENTAL
Intervention: Xanthohumol (XN) supplementation, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38358329

Group type: EXPERIMENTAL
Intervention: Subharmonic-aided pressure estimation (SHAPE) technique with Sonazoid microbubbles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care catheterization procedure
Number of subjects: 0
Study: 38358334

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously every 2 weeks and ipilimumab 1 mg/kg intravenously every 6 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 19
Study: 38358339

Group type: EXPERIMENTAL
Intervention: Zanidatamab (bispecific anti-HER2 antibody)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: MET inhibitors (single-agent and in combination with zanidatamab)
Number of subjects: 17
Study: 38358423

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (2.5 J, frequency 9.12 Hz, 904 nm for 10 min for 12 sessions)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham laser (control group)
Number of subjects: 31
Study: 38358542

Group type: EXPERIMENTAL
Intervention: Sintilimab plus bevacizumab (200 mg and 15 mg/kg respectively) combined with radiotherapy (30-50 Gy/10 fractions)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sintilimab plus bevacizumab combined with radiotherapy
Number of subjects: 46
Study: 38358703

Group type: EXPERIMENTAL
Intervention: Enhanced adaptive disclosure (AD-E)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Present-centered therapy (PCT)
Number of subjects: 174
Study: 38358711

Group type: EXPERIMENTAL
Intervention: Therapist Quality Scale (TQS)
Number of subjects: 66
Study: 38358753

Group type: EXPERIMENTAL
Intervention: pegargiminase-chemotherapy (36.8 mg/m2 weekly intramuscularly)
Number of subjects: 249

Group type: COMPARATOR
Intervention: placebo-chemotherapy
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: pegargiminase-chemotherapy
Number of subjects: 249
Study: 38358787

Group type: EXPERIMENTAL
Intervention: Bone@BC app
Number of subjects: 45
Study: 38359518

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 38359528

Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Chemo-break
Number of subjects: 214
Study: 38359542

Group type: EXPERIMENTAL
Intervention: START-Play intervention
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care early intervention (UC-EI)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Children with significant motor delays
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Children with mild motor delays
Number of subjects: 112
Study: 38359838

Group type: EXPERIMENTAL
Intervention: Immediate treatment with psilocybin-assisted psychotherapy (PAP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study: 38359854

Group type: COMPARATOR
Intervention: Rifasutenizol (50-1000 mg single doses)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Rifasutenizol (200-600 mg multiple doses, twice a day)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Triple regimen: 400 mg rifasutenizol, 20 mg rabeprazole, and 1 g amoxicillin twice a day for 14 days
Number of subjects: 246
Study: 38359938

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 224

Group type: COMPARATOR
Intervention: Radiography
Number of subjects: 224
Study: 38359941

Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF)
Number of subjects: 2874
Study: 38359944

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 1395
Study: 38360044

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Albumin 4% (control group)
Number of subjects: 28
Study: 38360182

Group type: EXPERIMENTAL
Intervention: Brolucizumab 6-mg
Number of subjects: 652

Group type: COMPARATOR
Intervention: Aflibercept 2-mg
Number of subjects: 652
Study: 38360261

Group type: EXPERIMENTAL
Intervention: Initial antiseizure medication (ASM)
Number of subjects: 39
Study: 38360334

Group type: EXPERIMENTAL
Intervention: CureSight (binocular eye-tracking-based home treatment)
Number of subjects: 43
Study: 38360452

Group type: EXPERIMENTAL
Intervention: Active rTMS (20 Hz, 30 pulses/train, 25 trains, 10-s intertrain interval) applied for either 2 or 4 weeks (5 days/week)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Sham rTMS applied for 4 weeks
Number of subjects: 135
Study: 38360485

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) - neural technique and area correction technique (group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) - area correction technique (group 2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study: 38360494

Group type: EXPERIMENTAL
Intervention: Washing of the whole body
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Showering
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Leave-on products application on the face
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Leave-on products application on the whole body
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Skin care interventions delivery
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Heterogeneity of product names
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Personal hygiene and cleansing interventions
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Daily washing
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Leave-on products usage
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Promotion of skin integrity
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Informed decision making
Number of subjects: 314